首頁 > 市場調查報告書 > 材料

市場調查報告書

商品編碼

1529382

全球獸用防腐劑市場 - 2024-2031

Global Veterinary Antiseptics Market - 2024-2031

出版日期: 2024年08月06日 | 出版商:

DataM Intelligence | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球獸用消毒劑市場規模達430.5億美元，預計2031年將達到833.1億美元，2024-2031年預測期間複合年成長率為8.6%。

獸用防腐劑是用來預防或減少動物皮膚和黏膜上微生物生長的外用製劑。它們用於消毒和清潔傷口，以及預防感染和促進癒合。

獸用消毒劑是含有抗菌劑的溶液、霜劑或軟膏，適用於家畜、伴侶動物和其他動物群體的傷口、割傷和其他容易感染的區域。

該市場是由動物傳染病的增加、獸醫學的進步以及寵物擁有量的增加等因素所推動的。

市場動態：

司機

動物傳染病的增加和獸醫學的進步

全球獸用防腐劑市場的需求是由多種因素所驅動的。主要因素之一是動物傳染病的增加，而獸醫的進步是獸用防腐劑市場的重要驅動力。

牲畜、伴侶動物和其他動物傳染病發病率的上升是獸用防腐劑市場的主要動力。在獸醫學中，抗菌劑和抗感染劑，例如抗真菌劑、抗病毒劑等，通常用於治療由細菌和其他微生物引起的感染性疾病。

根據世界動物衛生組織 (OIE) 的數據，過去 10 年報告的動物疾病爆發數量增加了 20%。疾病流行率的激增歸因於多種因素，包括氣候變遷、貿易和旅行的增加以及畜牧業實踐的變化。根據世界衛生組織2023年10月的資料，全球報告的新興傳染病中約60%來自動物。

此外，獸用抗菌劑領域的併購和創新推出等關鍵參與者策略預計將推動市場成長。例如，2024年3月，維克宣布與歐力士公司簽署最終協議，以約2.8億歐元的企業價值收購其動物保健子公司Sasaeah。

此外，2022 年 3 月，維克重新配製了 Vet Aquadent，這是一種用於日常飲用水的解決方案，可透過其 FR3SH 技術成分減少貓和狗的牙菌斑積聚。在治療劑或水添加劑中添加防腐劑是治療牙周病的一種有吸引力的方法。

限制

嚴格的法規、獸用防腐劑開發過程的高成本、個人缺乏認知以及新出現的抗藥性等因素預計將阻礙市場的發展。

有關此報告的更多詳細資訊 - 索取樣本

The rising incidence of infectious diseases in livestock, companion animals, and other animals is a major driver for the veterinary antiseptics market. In veterinary medicine, antibacterials and anti-infectives, such as antifungals, antivirals, and others, are commonly used to treat infectious disorders caused by bacteria and other microorganisms.

According to the World Organisation for Animal Health (OIE), the number of reported outbreaks of animal diseases has increased by 20% over the past decade. This surge in disease prevalence is attributed to various factors, including climate change, increased trade and travel, and changes in animal husbandry practices. According to WHO data in October 2023, some 60% of emerging infectious diseases that are reported globally come from animals.

Moreover, key player strategies such as mergers & acquisitions and innovative launches in the veterinary antiseptics are expected to drive market growth. For instance, in March 2024, Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Also, in March 2022, Virbac reformulated Vet Aquadent, the solution used in daily drinking water to reduce plaque build-up in cats and dogs, with its FR3SH technology ingredients. The addition of antiseptics to treats or water additives is an attractive method for treating periodontal disease.

Restraints

Factors such as stringent regulations, the high cost of the development process of veterinary antiseptics, lack of awareness among individuals, and emerging drug resistance, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global veterinary antiseptics market is segmented based on product type, route of administration, application, distribution channels, and region.

The livestock animal segment accounted for approximately 59.4% of the global veterinary antiseptics market share

The livestock animal segment is expected to hold the largest market share over the forecast period. Fish, poultry, swine, cattle, sheep, and goats are among the subcategories of the livestock segment. Growing everyday necessities, environmental sustainability, and rising meat consumption are all expected to contribute to this segment's significant expansion. For instance, the US Department of Agriculture (USDA) reported in May 2024 that from January to April 2024, the country produced approximately 8,863 million pounds of beef.

Moreover, the rising prevalence of infectious diseases in livestock animals helps to drive this segment's growth in the market. According to the Indian Council of Agriculture Research data published in 2023, during an outbreak of Lumpy skin diseases, 29.45 lakh cattle were infected and caused over 1.55 lakh deaths in over 15 states of India. Because India is a prominent dairy producer worldwide, this drives the demand for veterinary anti-infective drugs.

In addition, the increasing number of livestock, and the growing adoption of pets. A significant number of cattle and growing healthcare spending on veterinary care and animal health are additional significant factors anticipated to drive market expansion. For instance, in April 2024 data by USDA, nearly 30 percent of all cattle worldwide are found in China and India. The expanding population of livestock has boosted the demand for the production of meat and dairy products, which is predicted to fuel the demand for veterinary antibiotics for livestock animals.

Also, in March 2021, Zoetis announced the purchase of a 21-acre manufacturing site in Melbourne, to significantly expand its current operations at the site and increase future capabilities to develop and manufacture vaccines for sheep, cattle, dogs, cats, and horses.

Geographical Analysis

North America accounted for approximately 41.4% of the global veterinary antiseptics market share

North America will hold the largest market share over the forecast period owing to the growing pet ownership and companion animal population in the region. Increasing disposable incomes, urbanization, and changing lifestyles have led to a surge in pet adoptions, especially of dogs and cats, in countries such as the United States and Canada.

Veterinarians are increasingly adopting advanced antiseptic products and protocols to prevent and manage infections in both companion animals and livestock. This trend is supported by growing awareness among pet owners and farmers about the importance of infection control.

Moreover, the major number of key players' presence, well-advanced healthcare infrastructure, technological advancements, and product launches and approvals would propel this market growth in this region. For instance, in July 2023, Bimeda Inc. announced that SpectoGard (spectinomycin sulfate) Sterile Solution which received FDA approval in September of 2022-is available for veterinarians and cattle producers in the United States. SpectoGard Sterile Solution is the first bioequivalent, generic spectinomycin sulfate injectable solution that is approved for use in cattle for the treatment of bovine respiratory disease (pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

Similarly, in September 2023, the US Food and Drug Administration (FDA) released an updated 5-year action plan for supporting antimicrobial stewardship in veterinary settings. The plan from the FDA's Center for Veterinary Medicine (CVM) contains a series of actions organized under three goals.

Market Segmentation

By Product Type

Iodine & Iodophors
Chlorhexidine
Alcohol
Hydrogen Peroxide
Others

By Route of Administration

Oral
Injectable
Topical

By Application

Livestock Animal
- Poultry
- Swine
- Cattle
- Sheep & Goats
- Fish
- Others
Companion Animal
- Dogs
- Cats
- Others

By Distribution Channel

Veterinary Hospitals & Clinics
Retail Pharmacies & Pet Stores
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the veterinary antiseptics market include Zoetis Services LLC, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Dechra Pharmaceuticals PLC, Elanco, Ceva, Virbac, Biogenesis Bago, Vetoquinol and LABORATORIOS CALIER, S.A. among others.

Key Developments

In April 2024, Johnson's Veterinary Products added to its extensive health and wellbeing range with the introduction of two new balms aimed at dogs, cats, and small animals. The new products, an Antiseptic Balm and a Soothing Skin Balm for dogs, cats, and small animals, expand on the success of Johnson's existing Paw & Nose Balm for dogs, which launched last year, creating a trio of all-natural and vegan-friendly balms, that deliver a wide range of important healthcare benefits from soothing irritated skin to treating minor cuts and abrasions.
In January 2024, Merck Animal Health announced the European Commission (EC) has approved BRAVECTO (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs.
In February 2023, Dechra launched Tri-Solfen, a new topical anesthetic and antiseptic gel. The gel is easy to administer and fast-acting (effective in just 30 seconds), providing a practical tool to improve animal welfare via cutaneous and epilesional use.

Why Purchase the Report?

To visualize the global veterinary antiseptics market segmentation based on product type, route of administration, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global veterinary antiseptics market report would provide approximately 72 tables, 70 figures, and 184 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Route of Administration
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factor
- 4.1.1. Drivers
  - 4.1.1.1. Rise in Infectious Diseases among Animals and Advancement in Veterinary Medicine
  - 4.1.1.2. Increasing Pet Ownership
- 4.1.2. Restraints
  - 4.1.2.1. Stringent Regulations
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Iodine & Iodophors *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Chlorhexidine
6.4. Alcohol
6.5. Hydrogen Peroxide
6.6. Others

7. By Route of Administration

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Oral *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Topical
7.4. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
8.2. Livestock Animal *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Poultry
- 8.2.4. Swine
- 8.2.5. Cattle
- 8.2.6. Sheep & Goats
- 8.2.7. Fish
- 8.2.8. Others
8.3. Companion Animal
- 8.3.1. Dogs
- 8.3.2. Cats
- 8.3.3. Others

9. By Distribution Channels

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Veterinary Hospitals & Clinics *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies & Pet Stores
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Zoetis Services LLC *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Boehringer Ingelheim International GmbH
12.3. Merck & Co., Inc
12.4. Dechra Pharmaceuticals PLC
12.5. Elanco
12.6. Ceva
12.7. Virbac
12.8. Biogenesis Bago
12.9. Vetoquinol
12.10. LABORATORIOS CALIER, S.A.

LIST NOT EXHAUSTIVE